Found: 69
Select item for more details and to access through your institution.
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 172, doi. 10.1007/s10637-019-00801-8
- By:
- Publication type:
- Article
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 4, p. 382, doi. 10.1111/hepr.13991
- By:
- Publication type:
- Article
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 1031, doi. 10.1111/hepr.13934
- By:
- Publication type:
- Article
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
- Published in:
- Hepatology Research, 2023, v. 53, n. 8, p. 737, doi. 10.1111/hepr.13905
- By:
- Publication type:
- Article
Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2022, v. 52, n. 12, p. 1060, doi. 10.1111/hepr.13827
- By:
- Publication type:
- Article
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
- Published in:
- Hepatology Research, 2022, v. 52, n. 12, p. 1050, doi. 10.1111/hepr.13824
- By:
- Publication type:
- Article
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice.
- Published in:
- Hepatology Research, 2022, v. 52, n. 9, p. 773, doi. 10.1111/hepr.13797
- By:
- Publication type:
- Article
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 462, doi. 10.1111/hepr.13748
- By:
- Publication type:
- Article
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 308, doi. 10.1111/hepr.13734
- By:
- Publication type:
- Article
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
- Published in:
- Hepatology Research, 2021, v. 51, n. 8, p. 880, doi. 10.1111/hepr.13644
- By:
- Publication type:
- Article
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
- Published in:
- Hepatology Research, 2021, v. 51, n. 2, p. 201, doi. 10.1111/hepr.13592
- By:
- Publication type:
- Article
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 6, p. 565, doi. 10.1159/000530078
- By:
- Publication type:
- Article
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
- By:
- Publication type:
- Article
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
- By:
- Publication type:
- Article
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 473, doi. 10.1159/000515552
- By:
- Publication type:
- Article
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
- By:
- Publication type:
- Article
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 6, p. 734, doi. 10.1159/000508971
- By:
- Publication type:
- Article
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 4, p. 382, doi. 10.1159/000507022
- By:
- Publication type:
- Article
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.
- Published in:
- Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
- By:
- Publication type:
- Article
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma.
- Published in:
- Liver International, 2024, v. 44, n. 1, p. 113, doi. 10.1111/liv.15753
- By:
- Publication type:
- Article
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Liver International, 2020, v. 40, n. 4, p. 968, doi. 10.1111/liv.14405
- By:
- Publication type:
- Article
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching.
- Published in:
- Hepatology Research, 2020, v. 50, n. 1, p. 75, doi. 10.1111/hepr.13427
- By:
- Publication type:
- Article
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.
- Published in:
- Hepatology Research, 2019, v. 49, n. 1, p. 111, doi. 10.1111/hepr.13243
- By:
- Publication type:
- Article
A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin–bilirubin grade.
- Published in:
- Hepatology Research, 2018, v. 48, n. 3, p. E61, doi. 10.1111/hepr.12927
- By:
- Publication type:
- Article
Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.
- Published in:
- Hepatology Research, 2016, v. 46, n. 8, p. 734, doi. 10.1111/hepr.12613
- By:
- Publication type:
- Article
Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.
- Published in:
- Hepatology Research, 2016, v. 46, n. 6, p. 521, doi. 10.1111/hepr.12583
- By:
- Publication type:
- Article
Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, n. 5, p. N.PAG, doi. 10.1093/ofid/ofz185
- By:
- Publication type:
- Article
Effects of Early Initiation of Solid Versus Liquid Diet after Endoscopic Submucosal Dissection on Quality of Life and Postoperative Outcomes: A Prospective Pilot Randomized Controlled Trial.
- Published in:
- Digestion, 2019, v. 100, n. 3, p. 160, doi. 10.1159/000494490
- By:
- Publication type:
- Article
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
- Published in:
- Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
- By:
- Publication type:
- Article
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
- Published in:
- Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
- By:
- Publication type:
- Article
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
- By:
- Publication type:
- Article
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
- By:
- Publication type:
- Article
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
- Published in:
- Oncology, 2022, v. 100, n. 2, p. 65, doi. 10.1159/000520292
- By:
- Publication type:
- Article
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
- Published in:
- Oncology, 2021, v. 99, n. 8, p. 518, doi. 10.1159/000515896
- By:
- Publication type:
- Article
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2020, v. 98, n. 5, p. 295, doi. 10.1159/000506293
- By:
- Publication type:
- Article
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 6, p. 334, doi. 10.1159/000502095
- By:
- Publication type:
- Article
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2019, v. 97, n. 5, p. 277, doi. 10.1159/000501281
- By:
- Publication type:
- Article
Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.
- Published in:
- Oncology, 2016, v. 91, n. 3, p. 153, doi. 10.1159/000447061
- By:
- Publication type:
- Article
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
- Published in:
- Cancer Reports, 2024, v. 7, n. 4, p. 1, doi. 10.1002/cnr2.2042
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
- Published in:
- Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1464
- By:
- Publication type:
- Article
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
- By:
- Publication type:
- Article
Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.
- Published in:
- Liver Cancer International, 2023, v. 4, n. 3, p. 101, doi. 10.1002/lci2.74
- By:
- Publication type:
- Article
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 8, p. 3719, doi. 10.1002/cam4.2241
- By:
- Publication type:
- Article
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 1, p. 137, doi. 10.1002/cam4.1909
- By:
- Publication type:
- Article
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 4, p. 394, doi. 10.1007/s10637-024-01441-3
- By:
- Publication type:
- Article
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents.
- Published in:
- Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 7, p. 1394, doi. 10.1111/jgh.16553
- By:
- Publication type:
- Article
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
- Published in:
- Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 5, p. 949, doi. 10.1111/jgh.16494
- By:
- Publication type:
- Article
Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
- Published in:
- Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
- By:
- Publication type:
- Article
Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
- Published in:
- Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 7, p. 1812, doi. 10.1111/jgh.15336
- By:
- Publication type:
- Article
Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study.
- Published in:
- 2021
- By:
- Publication type:
- journal article